Peptic Ulcer Drugs Market By Product Type (H2 receptor Antagonists, Proton Pump Inhibitors (PPIs), Antacids, Ulcer Protective Drugs, Potassium-Competitive Acid Blockers (P-CAB), Antibiotics, Others), By Formulation (Oral tablets, Effervescent Tablets, Effervescent Granules, Syrups, Injections), By Application (Gastroesophagal Reflux Disease (GERD), Gastritis, Duodenal Ulcers, Gastric Ulcers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography    

Purchase Option

$ 4400
$ 6600
$ 8900

Peptic Ulcer Drugs Market was valued at USD 4,378.2 million in 2022 and is anticipated to grow at a CAGR of 4.1 % over 2023-2029. Peptic ulcers are open sores that form on the lining of the stomach, upper small intestine, or esophagus and are often brought on by the erosion of the protective mucous layer due to an overabundance of gastric acid output or an infection with the bacterium Helicobacter pylori. Peptic ulcers may produce a number of symptoms, including bloating, nausea, vomiting, stomach discomfort, and if left untreated, they can lead to complications such as bleeding, perforation, and blockage of the digestive tract. Drugs for peptic ulcers are intended to treat gastric ulcers, duodenal ulcers, gastro-oesophageal reflux disease (GORD) and prevent subsequent problems. Peptic ulcers are a common gastrointestinal disorder affecting millions of people worldwide. The high prevalence of peptic ulcers drives the demand for effective drugs for their treatment, ultimately aiding in the growth of the peptic ulcer drugs market.

According to a research study, four million individuals worldwide suffer from peptic ulcer disease (PUD) each year, with a lifetime prevalence of 5–10% in the general population. Moreover, technological advancements in drug formulations along with rising healthcare expenditure drive the peptic ulcer drugs market as well as create significant opportunities to develop new solutions to treat peptic ulcers such as innovative delivery systems like controlled-release formulations or targeted drug delivery and novel drug formulation, such as combination therapies. However, side effects and safety concerns are posing challenges to the growth of the peptic ulcers market. Various pharmaceutical companies are adapting their strategies to develop innovative products and meet the changing demands of patients and healthcare systems worldwide. For instance, in April 2023, Akums Drugs and Pharmaceutical launched Combikit for the treatment of Duodenal Ulcer and H. pylori infection.

Peptic Ulcer Drugs Market Key Developments:
  • In August 2022, the peptic ulcer drug Dartisla ODT manufactured by Edenbridge Pharmaceuticals received FDA approval.
  • In August 2021, Dr Reddy's Laboratories launched generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules for the treatment of stomach ulcers, irritable bowel syndrome, and inflammation of the colon, in the US market.

Global Peptic Ulcer Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.1%

Largest Market

North America

Fastest Growing Market

North America
Peptic Ulcer Drugs Market Dynamics

Increase in the global geriatric population, rise in prevalence of peptic ulcers due to change in food habits, and increase in the consumption of tobacco and alcohol are key factors surge the global peptic ulcer drugs market. Moreover, rise in R&D for the development of newer drugs, rise in number of drug induced peptic ulcer cases, availability of cost-effective drugs, and rise in awareness about the peptic ulcers among the people are anticipated to surge the global peptic ulcer drugs market over the forecast years. However, adverse effects associated with the drugs, patent expiries of block buster drugs, poor pipeline products, and changes in pricing policies are hamper the growth of global peptic ulcer drugs market.

Key Features of the Reports

  • The peptic ulcer drugs market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup's details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Global Peptic Ulcer Drugs Market Segmentation

By Product Type
  • H2 receptor Antagonists
  • Proton Pump Inhibitors (PPIs)
  • Antacids
  • Ulcer Protective Drugs
  • Potassium-Competitive Acid Blockers (P-CAB)
  • Antibiotics
  • Others
By Formulation
  • Oral tablets
  • Effervescent Tablets
  • Effervescent Granules
  • Syrups
  • Injections
By Application
  • Gastroesophagal Reflux Disease (GERD)
  • Gastritis
  • Duodenal Ulcers
  • Gastric Ulcers
  • Others
By Geography
  • North America,
  • Latin America,
  • Europe,
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

The peptic ulcer drugs market is projected to expand at a CAGR of 4.1% during the forecast period.  

Pfizer, Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Abbott Laboratories (U.S.), Takeda Pharmaceuticals Co. Ltd (Japan), GlaxoSmithKline plc (UK)

North America is the fastest-growing region for the peptic ulcer drugs market

1.Executive Summary
2.Global Peptic Ulcer Drugs Market Introduction 
2.1.Global Peptic Ulcer Drugs Market  - Taxonomy
2.2.Global Peptic Ulcer Drugs Market  - Definitions
2.2.1. By Product Type
2.2.2. By Formulation
2.2.3. By Application
2.2.4. By Region
3.Global Peptic Ulcer Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Peptic Ulcer Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Peptic Ulcer Drugs Market  By Product Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. H2 receptor Antagonists
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Proton Pump Inhibitors (PPIs)
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Antacids
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Ulcer Protective Drugs
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Potassium-Competitive Acid Blockers (P-CAB)
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Antibiotics
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Others
5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
6.Global Peptic Ulcer Drugs Market  By Formulation, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Oral tablets
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Effervescent Tablets
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Effervescent Granules
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Syrups
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Injections
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Peptic Ulcer Drugs Market  By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Gastroesophagal Reflux Disease (GERD)
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Gastritis
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Duodenal Ulcers
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Gastric Ulcers
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Others
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.Global Peptic Ulcer Drugs Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Peptic Ulcer Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.H2 receptor Antagonists
9.1.2.Proton Pump Inhibitors (PPIs)
9.1.3.Antacids
9.1.4.Ulcer Protective Drugs
9.1.5.Potassium-Competitive Acid Blockers (P-CAB)
9.1.6.Antibiotics
9.1.7.Others
9.2.  Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral tablets
9.2.2.Effervescent Tablets
9.2.3.Effervescent Granules
9.2.4.Syrups
9.2.5.Injections
9.3.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Gastroesophagal Reflux Disease (GERD)
9.3.2.Gastritis
9.3.3.Duodenal Ulcers
9.3.4.Gastric Ulcers
9.3.5.Others
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Peptic Ulcer Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.H2 receptor Antagonists
10.1.2.Proton Pump Inhibitors (PPIs)
10.1.3.Antacids
10.1.4.Ulcer Protective Drugs
10.1.5.Potassium-Competitive Acid Blockers (P-CAB)
10.1.6.Antibiotics
10.1.7.Others
10.2.  Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral tablets
10.2.2.Effervescent Tablets
10.2.3.Effervescent Granules
10.2.4.Syrups
10.2.5.Injections
10.3.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Gastroesophagal Reflux Disease (GERD)
10.3.2.Gastritis
10.3.3.Duodenal Ulcers
10.3.4.Gastric Ulcers
10.3.5.Others
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Peptic Ulcer Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.H2 receptor Antagonists
11.1.2.Proton Pump Inhibitors (PPIs)
11.1.3.Antacids
11.1.4.Ulcer Protective Drugs
11.1.5.Potassium-Competitive Acid Blockers (P-CAB)
11.1.6.Antibiotics
11.1.7.Others
11.2.  Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral tablets
11.2.2.Effervescent Tablets
11.2.3.Effervescent Granules
11.2.4.Syrups
11.2.5.Injections
11.3.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Gastroesophagal Reflux Disease (GERD)
11.3.2.Gastritis
11.3.3.Duodenal Ulcers
11.3.4.Gastric Ulcers
11.3.5.Others
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Peptic Ulcer Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.H2 receptor Antagonists
12.1.2.Proton Pump Inhibitors (PPIs)
12.1.3.Antacids
12.1.4.Ulcer Protective Drugs
12.1.5.Potassium-Competitive Acid Blockers (P-CAB)
12.1.6.Antibiotics
12.1.7.Others
12.2.  Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral tablets
12.2.2.Effervescent Tablets
12.2.3.Effervescent Granules
12.2.4.Syrups
12.2.5.Injections
12.3.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Gastroesophagal Reflux Disease (GERD)
12.3.2.Gastritis
12.3.3.Duodenal Ulcers
12.3.4.Gastric Ulcers
12.3.5.Others
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Peptic Ulcer Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.H2 receptor Antagonists
13.1.2.Proton Pump Inhibitors (PPIs)
13.1.3.Antacids
13.1.4.Ulcer Protective Drugs
13.1.5.Potassium-Competitive Acid Blockers (P-CAB)
13.1.6.Antibiotics
13.1.7.Others
13.2.  Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral tablets
13.2.2.Effervescent Tablets
13.2.3.Effervescent Granules
13.2.4.Syrups
13.2.5.Injections
13.3.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Gastroesophagal Reflux Disease (GERD)
13.3.2.Gastritis
13.3.3.Duodenal Ulcers
13.3.4.Gastric Ulcers
13.3.5.Others
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Pfizer, Inc. (U.S.)
14.2.2.Boehringer Ingelheim GmbH (Germany)
14.2.3.Abbott Laboratories (U.S.)
14.2.4.Takeda Pharmaceuticals Co. Ltd (Japan)
14.2.5.GlaxoSmithKline plc (UK)
14.2.6.Yuhan Co. Ltd. (South Korea)
14.2.7.AstraZeneca plc (UK)
14.2.8.Eisai Co. Ltd. (U.S.)
14.2.9.Helicure AB (Sweden)
14.2.10.Cadila Healthcare (India)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Pfizer, Inc. (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Abbott Laboratories (U.S.)
  • Takeda Pharmaceuticals Co. Ltd (Japan)
  • GlaxoSmithKline plc (UK)
  • Yuhan Co. Ltd. (South Korea)
  • AstraZeneca plc (UK)
  • Eisai Co. Ltd. (U.S.)
  • Helicure AB (Sweden)
  • Cadila Healthcare (India)

Adjacent Markets